Q-Med's election committee presents its proposal for a new Board

Q-Med's election committee presents its proposal for a new Board

As has been announced previously, Lyftet Holding BV has requested an
Extraordinary General Meeting of the shareholders to elect a new Board for 
Q-Med AB. In this connection the election committee presents the following
proposal, for resolution at the Extraordinary General Meeting on February 4. The
election committee's proposal has the support of owners representing just under
70 percent of the total number of shares in the company.

The election committee consists of:	

Robert Wikholm, Chairman
Anders Milton
Jan-Erik Erenius, AMF Pension

It is proposed that Bertil Hult, a member of the Board of Q-Med since 2006, be
re-elected. He is the CEO of the Skandia Insurance Company (publ) and CEO of
Skandia's Nordic Division. Bertil Hult is, amongst other things, Chairman of
Asia Growth Investors AB and eTurn Capital Management AB, and has a number of
Board assignments in Skandia.

It is proposed that Anders Milton, a member of the Board of Q-Med since 1997, be
re-elected and that he become Chairman of the Board. Anders Milton is, amongst
other things, Chairman of dagens.ps AB, ERNA (The European Red Cross/Red
Crescent Network on HIV/AIDS and Tuberculosis), Europaskolan Strängnäs, Vironova
AB and the Face of Aids Foundation and a member of the Board of Charity Rating,
HealthSolutions AB, Transvoice AB and WeMind AB.

It is proposed that Bengt Ågerup, a member of the Board of Q-Med since 1987, be
re-elected. He is Q-Med's founder, President and CEO. Bengt Ågerup is the
Chairman of Stockholm-Uppsala Life Science and OxThera AB and a member of the
Board of Envirotainer AB and of the Swedish Foundation for Strategic Research.

It is proposed that Ulf Mattson be elected as a new member of the Board. He has
an M. Sc. in Business and Economics from Stockholm University, has been a
postgraduate student at Stockholm University and has a PMD from Harvard Business
School. He has been CEO of Capio AB (publ), Mölnlycke Health Care AB and Domco
Tarkett Inc. (publ), based in Montreal. Ulf Mattson is, amongst other things,
Chairman of Flextrus AB, Pahlén AB and a member of the Board of Securitas Direct
AB NSS Group AB, Din Bostad AB (publ) and Pelly Industrier AB.   

It is proposed that Tomas Nicolin be elected as a new member of the Board. He
has an M.Sc. in Business and Economics from the Stockholm School of Economics
and an M.Sc. in Management from MIT Sloan School of Management, Cambridge USA.
He has, amongst other things, been the CEO of Alecta, the Third Swedish National
Pension Fund and E.Öhman J:or Fondkommission AB, as well as Head of
Handelsbanken Markets Asset Management. Tomas Nicolin is, amongst other things,
a member of the Board of Nordstjernan AB, Axel and Margaret Ax:son Johnson's
Foundation, the Research Institute of Industrial Economics and the Swedish
Industry and Commerce Stock Exchange Committee. 
It is proposed that Kristina Persson be elected as a new member of the Board.
She has an M.Sc. in Business and Economics from the Stockholm School of
Economics. She is the executive Chairman of the Global Challenge association and
has previously been, amongst other things, Deputy Governor at the Swedish
Riksbank, the County Governor of Jämtland and a member of the Swedish
Parliament.  Kristina Persson is, amongst other things, Chairman of the Norden
Association and a member of the Board of the Mid Sweden University, the African
Wildlife Association, The Natural Step and The Swedish Institute of
International Affairs.




Questions should be addressed to:
Robert Wikholm, Chairman of the Election Committee, tel: +46 (0)70 - 714 31 77




Q-Med AB is a rapidly growing and profitable biotechnology/medical device
company. The company develops, manufactures, markets, and sells primarily
medical implants. The majority of the products are based on the company's
patented technology, NASHA™, for the production of stabilized non-animal
hyaluronic acid. The product portfolio today contains: Restylane® for filling
lines and folds, contouring and creating volume in the face, Macrolane™ for body
contouring, Durolane™ for the treatment of osteoarthritis of the hip and knee
joints, Deflux® for the treatment of vesicoureteral reflux, VUR, (a malformation
of the urinary bladder) in children, and Solesta™ for the treatment of fecal
incontinence. Sales are made through the company's own subsidiaries or
distributors in over 70 countries. Q Med today has just over 700 coworkers, with
close to 500 at the company's head office and production facility in Uppsala,
Sweden. Q-Med AB is listed in the Mid Cap segment of the OMX Nordic Exchange in
Stockholm.


Q-Med AB (publ), Seminariegatan 21, SE-752 28 Uppsala, Sweden. Corporate
identity number 556258-6882.
Tel: +46(0)18-474 90 00. Fax: +46(0)18-474 90 01. E-mail: info@q-med.com. Web:
www.q-med.com.

In USA, Q-Med AB's affiliate is the wholly-owned subsidiary Q-Med Scandinavia,
Inc.